Intellipharmaceutics Provides Operational Update
24 janv. 2018 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Receipt of Nasdaq Notice
05 déc. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
30 nov. 2017 10h45 HE
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) and (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in...
Intellipharmaceutics Announces Closing of US$4 Million Financing
13 oct. 2017 17h45 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces US$4 Million Registered Direct Offering
11 oct. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Third Quarter 2017 Results
10 oct. 2017 17h20 HE
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
25 sept. 2017 07h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Receipt of Nasdaq Notice
20 sept. 2017 17h10 HE
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Operational Update
05 sept. 2017 14h35 HE
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Appoints New Chief Financial Officer
01 sept. 2017 08h00 HE
|
Intellipharmaceutics International Inc.
TORONTO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...